tirzepatide and hormones caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Tirzepatide Hormone Therapy: The 35%

states grant NPs full practice authoritymeaning you can evaluate, diagnose, and prescribe independently without physician oversight

2019;176:435-447.e15

Summary of GLP1 adoption trends in Europe GLP1 uptake in Europe remains far lower than US levels Consumer scepticism across Europe limits weightloss drug use despite rising awareness Public healthcare coverage constraints slow adoption compared with commercially driven US Even optimistic scenarios predict only modest calorieintake reductions across Europe Gradual destigmatisation suggests slow growth but limited longterm market disruption GLP-1 receptor agonists have seen far greater traction in the US than in Europe

Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart